News Digest / Ticker: ACRS

Ticker: ACRS

09:49am, Wednesday, Jun 25, 2025
Aclaris Therapeutics (NASDAQ: ACRS) begins a Phase 1 trial for its bispecific antibody ATI-052, targeting inflammation. H.C. Wainwright maintains a "Buy" rating with a $16 price target. Key results expected in 2026 may impact stock volatility and investment strategies.